Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16011845 | 0.78 | EPHX1 (0.46) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL13263062 | 0.74 | HDAC4 (0.47) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL30988818 | 0.72 | CES2 (0.49) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL16419139 | 0.72 | CES2 (0.49) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL576436 | 0.72 | IDO1 (0.50) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL25270476 | 0.72 | HDAC4 (0.46) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL17660052 | 0.72 | CES2 (0.49) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL576210 | 0.72 | IDO1 (0.55) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL16958819 | 0.72 | HDAC4 (0.46) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL16412814 | 0.72 | CES2 (0.49) | HDAC4HDAC7HDAC5CNR2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | ALIOS BIOPHARMA, INC. (US) | 2019-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | PNPO, ITPA, PDXK | HDAC4 193/4885HDAC7 424/4885HDAC5 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.